Suppr超能文献

草药抑制剂 SARS-CoV-2 M 可有效改善小鼠的急性肺损伤。

Herbal inhibitors of SARS-CoV-2 M effectively ameliorate acute lung injury in mice.

机构信息

State Key Laboratory of Medical Molecular Biology, Institute of Basic Medical Sciences Chinese Academy of Medical Sciences, Department of Biochemistry, School of Basic Medicine Peking Union Medical College, Beijing, China.

National Kunming High-level Biosafety Primate Research Center, Institute of Medical Biology, Chinese Academy of Medical Sciences and Peking Union Medical College, Yunnan, China.

出版信息

IUBMB Life. 2022 Jun;74(6):532-542. doi: 10.1002/iub.2616. Epub 2022 Apr 22.

Abstract

Coronavirus disease 2019, a newly emerging serious infectious disease, has spread worldwide. To date, effective drugs against the disease are limited. Traditional Chinese medicine was commonly used in treating COVID-19 patients in China. Here we tried to identify herbal effective lipid compounds from the lipid library of 92 heat-clearing and detoxication Chinese herbs. Through virtual screening, enzymatic activity and inhibition assays, and surface plasmon resonance tests, we identified lipid compounds targeting the main protease (M ) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and verified their functions. Here, we found that natural lipid compounds LPC (14:0/0:0) and LPC (16:0/0:0) could target SARS-CoV-2 M , recover cell death induced by SARS-CoV-2, and ameliorate acute lung injury (ALI)/acute respiratory distress syndrome (ARDS) induced by bacterial lipopolysaccharides and virus poly (I:C) mimics in vivo and in vitro. Our results suggest that LPC (14:0/0:0) and LPC (16:0/0:0) might be potential pan remedy against ARDS.

摘要

新型冠状病毒病(COVID-19)是一种新出现的严重传染病,已在全球范围内传播。迄今为止,针对该疾病的有效药物有限。中药在中国常用于治疗 COVID-19 患者。在这里,我们试图从 92 种清热解毒中药的脂质库中鉴定针对严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)主要蛋白酶(M )的草药有效脂质化合物。通过虚拟筛选、酶活性和抑制测定以及表面等离子体共振试验,我们鉴定了针对 SARS-CoV-2 M 的脂质化合物,并验证了它们的功能。在这里,我们发现天然脂质化合物 LPC(14:0/0:0)和 LPC(16:0/0:0)可以靶向 SARS-CoV-2 M ,恢复由 SARS-CoV-2 诱导的细胞死亡,并改善由细菌脂多糖和病毒多聚(I:C)模拟物在体内和体外诱导的急性肺损伤(ALI)/急性呼吸窘迫综合征(ARDS)。我们的研究结果表明,LPC(14:0/0:0)和 LPC(16:0/0:0)可能是治疗 ARDS 的潜在泛疗法。

相似文献

1
Herbal inhibitors of SARS-CoV-2 M effectively ameliorate acute lung injury in mice.
IUBMB Life. 2022 Jun;74(6):532-542. doi: 10.1002/iub.2616. Epub 2022 Apr 22.
2
Nitazoxanide and COVID-19: A review.
Mol Biol Rep. 2022 Nov;49(11):11169-11176. doi: 10.1007/s11033-022-07822-2. Epub 2022 Sep 12.
3
The role of berberine in Covid-19: potential adjunct therapy.
Inflammopharmacology. 2022 Dec;30(6):2003-2016. doi: 10.1007/s10787-022-01080-1. Epub 2022 Oct 2.
4
Effective inhibition of coronavirus replication by .
Front Biosci (Landmark Ed). 2021 Oct 30;26(10):789-798. doi: 10.52586/4988.
5
Orally administered BZL-sRNA-20 oligonucleotide targeting TLR4 effectively ameliorates acute lung injury in mice.
Sci China Life Sci. 2023 Jul;66(7):1589-1599. doi: 10.1007/s11427-022-2219-0. Epub 2023 Feb 13.
6
Ursolic acid and SARS-CoV-2 infection: a new horizon and perspective.
Inflammopharmacology. 2022 Oct;30(5):1493-1501. doi: 10.1007/s10787-022-01038-3. Epub 2022 Aug 3.
7
A multi-stage virtual screening of FDA-approved drugs reveals potential inhibitors of SARS-CoV-2 main protease.
J Biomol Struct Dyn. 2022 Mar;40(5):2327-2338. doi: 10.1080/07391102.2020.1837680. Epub 2020 Oct 23.
9
Current approaches for target-specific drug discovery using natural compounds against SARS-CoV-2 infection.
Virus Res. 2020 Dec;290:198169. doi: 10.1016/j.virusres.2020.198169. Epub 2020 Sep 24.

引用本文的文献

1
Serum metabolic alterations in chickens upon infectious bursal disease virus infection.
BMC Vet Res. 2024 Dec 19;20(1):569. doi: 10.1186/s12917-024-04402-3.
2
Protective effects of yeast extract against alcohol-induced liver injury in rats.
Front Microbiol. 2023 Jul 20;14:1217449. doi: 10.3389/fmicb.2023.1217449. eCollection 2023.
3
Bioactive natural products in COVID-19 therapy.
Front Pharmacol. 2022 Aug 19;13:926507. doi: 10.3389/fphar.2022.926507. eCollection 2022.

本文引用的文献

2
The main protease and RNA-dependent RNA polymerase are two prime targets for SARS-CoV-2.
Biochem Biophys Res Commun. 2021 Jan 29;538:63-71. doi: 10.1016/j.bbrc.2020.10.091. Epub 2020 Nov 21.
3
COVID-19: Discovery, diagnostics and drug development.
J Hepatol. 2021 Jan;74(1):168-184. doi: 10.1016/j.jhep.2020.09.031. Epub 2020 Oct 8.
4
SARS-CoV-2 vaccines in development.
Nature. 2020 Oct;586(7830):516-527. doi: 10.1038/s41586-020-2798-3. Epub 2020 Sep 23.
5
Dexamethasone in Hospitalized Patients with Covid-19.
N Engl J Med. 2021 Feb 25;384(8):693-704. doi: 10.1056/NEJMoa2021436. Epub 2020 Jul 17.
7
[Clinical Characteristics and Coping Strategies of Neoplasms with 2019 Novel Coronavirus Infection].
Zhongguo Fei Ai Za Zhi. 2020 Apr 20;23(4):261-266. doi: 10.3779/j.issn.1009-3419.2020.102.15.
8
Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α-ketoamide inhibitors.
Science. 2020 Apr 24;368(6489):409-412. doi: 10.1126/science.abb3405. Epub 2020 Mar 20.
9
COVID-19: consider cytokine storm syndromes and immunosuppression.
Lancet. 2020 Mar 28;395(10229):1033-1034. doi: 10.1016/S0140-6736(20)30628-0. Epub 2020 Mar 16.
10
Histopathologic Changes and SARS-CoV-2 Immunostaining in the Lung of a Patient With COVID-19.
Ann Intern Med. 2020 May 5;172(9):629-632. doi: 10.7326/M20-0533. Epub 2020 Mar 12.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验